Vivos Therapeutics has signed a collaboration agreement with a multi-location Florida cardiology group to bring its oral appliance-based sleep apnea and insomnia diagnostic and treatment protocols directly into cardiovascular patient care pathways. The partnership underscores a broadening clinical consensus that untreated obstructive sleep apnea (OSA) is a meaningful comorbidity driver in cardiometabolic disease — territory that functional food and nutraceutical brands have increasingly moved into with condition-specific finished formulations.
Vivos's platform centers on biomimetic oral devices designed to address the structural contributors to OSA rather than relying solely on CPAP adherence. By embedding sleep-disorder screening and treatment within a cardiology workflow, the agreement creates a point-of-care environment where adjunctive wellness interventions — including magnesium glycinate, L-theanine, and standardized ashwagandha extract — could eventually complement device-based therapy, though Vivos has not announced any nutraceutical co-formulation partnerships at this stage.
The sleep health supplement category is a material market backdrop here. Consumer demand for sleep-support products has pushed the segment into one of the fastest-growing verticals within the broader wellness space, with clinical endpoints such as sleep latency, overnight cortisol reduction, and subjective sleep quality scores becoming standard language in structure-function claims. Brands carrying magnesium or adaptogen-forward SKUs through the cardiology and integrative-medicine channel are already positioning sleep as a cardiovascular risk-reduction story — a narrative this Vivos deal amplifies.
For operators and formulators watching distribution trends, the cardiology group channel represents an emerging retail-adjacent touchpoint. Practitioners in this setting are increasingly receptive to evidence-backed nutraceuticals that carry peer-reviewed support and clean label positioning, particularly products with GRAS status or established safety dossiers. Co-manufacturing partners capable of producing low-dose, practitioner-channel formats — think 200 mg/serving magnesium bisglycinate or 300 mg standardized ashwagandha (KSM-66 or Sensoril) — are well placed to supply this growing segment. Coverage of adjacent sleep-and-stress ingredient innovation can be found in our adaptogen and stress-support roundup and our analysis of the practitioner channel nutraceutical opportunity.
The Vivos-Florida cardiology collaboration does not disclose financial terms or patient-volume projections, but it reflects a structural shift: sleep health is no longer siloed in sleep clinics or DTC supplement aisles. As cardiologists become gatekeepers for OSA diagnosis, the functional nutrition industry has a credible new channel to develop — provided it brings the clinical substantiation to match.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.